Dupixent could dominate pediatric eczema market for up to a decade, analysis finds

Sanofi and Regeneron will be able to call themselves market leaders within atopic eczema treatment for children aged 6 months to 5 for years to come, according to Globaldata.

Photo: Brendan Mcdermid/Reuters/Ritzau Scanpix

Sanofi and Regeneron have a multi-blockbuster drug in their possession, Dupixent (dupilumab) against atopic eczema, and despite competition from Leo Pharma’s Adtralza (tralokinumab) and others, no one will be able to pose a threat to Dupixent’s market position for years to come, an analysis conducted by Globaldata concludes.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs